WCM Investment Management LLC Has $384.17 Million Position in Illumina, Inc. $ILMN

WCM Investment Management LLC lowered its holdings in Illumina, Inc. (NASDAQ:ILMN) by 5.5% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 4,181,681 shares of the life sciences company’s stock after selling 244,790 shares during the period. WCM Investment Management LLC owned approximately 2.72% of Illumina worth $384,171,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also modified their holdings of the business. Parkside Financial Bank & Trust boosted its position in Illumina by 65.7% during the 2nd quarter. Parkside Financial Bank & Trust now owns 290 shares of the life sciences company’s stock worth $28,000 after acquiring an additional 115 shares during the period. Quent Capital LLC purchased a new stake in shares of Illumina in the third quarter worth approximately $29,000. Cullen Frost Bankers Inc. acquired a new stake in shares of Illumina during the second quarter worth approximately $41,000. NewSquare Capital LLC grew its position in Illumina by 604.9% during the second quarter. NewSquare Capital LLC now owns 430 shares of the life sciences company’s stock valued at $41,000 after purchasing an additional 369 shares in the last quarter. Finally, Mather Group LLC. purchased a new position in Illumina during the third quarter valued at approximately $46,000. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Insiders Place Their Bets

In other Illumina news, insider Scott M. Davies sold 323 shares of the company’s stock in a transaction that occurred on Friday, December 12th. The stock was sold at an average price of $136.09, for a total transaction of $43,957.07. Following the completion of the sale, the insider owned 17,887 shares of the company’s stock, valued at $2,434,241.83. This represents a 1.77% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.17% of the company’s stock.

Illumina Price Performance

Shares of NASDAQ:ILMN opened at $141.13 on Tuesday. The stock has a market capitalization of $21.56 billion, a P/E ratio of 31.64, a P/E/G ratio of 2.40 and a beta of 1.45. The business has a 50-day moving average of $138.39 and a two-hundred day moving average of $115.46. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $155.53. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.43 and a quick ratio of 1.12.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on ILMN shares. Evercore ISI reissued an “outperform” rating and set a $155.00 target price on shares of Illumina in a research note on Monday, January 5th. Canaccord Genuity Group lifted their price objective on Illumina from $130.00 to $150.00 and gave the company a “hold” rating in a research report on Monday, January 26th. Stifel Nicolaus boosted their target price on Illumina from $135.00 to $155.00 and gave the company a “buy” rating in a research note on Tuesday, January 20th. JPMorgan Chase & Co. raised their price target on Illumina from $105.00 to $130.00 and gave the stock a “neutral” rating in a research note on Monday, December 15th. Finally, UBS Group boosted their price target on Illumina from $110.00 to $120.00 and gave the company a “neutral” rating in a research note on Friday, October 31st. Six investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, Illumina currently has an average rating of “Hold” and a consensus target price of $127.18.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.